Fig. 2: Levels of HRF/TCTP in patients with rheumatoid arthritis (RA) and their relationship with disease severity. | Experimental & Molecular Medicine

Fig. 2: Levels of HRF/TCTP in patients with rheumatoid arthritis (RA) and their relationship with disease severity.

From: Blockade of translationally controlled tumor protein attenuated the aggressiveness of fibroblast-like synoviocytes and ameliorated collagen-induced arthritis

Fig. 2: Levels of HRF/TCTP in patients with rheumatoid arthritis (RA) and their relationship with disease severity.

a Levels of HRF/TCTP in the sera of healthy controls (HC, n = 15) and patients with osteoarthritis (OA, n = 20), ankylosing spondylitis (AS, n = 23), Behçet’s disease (BD, n = 26), early RA (ERA, disease duration <1 year, n = 21), and advanced RA (ARA, disease duration ≥1 year, n = 17), as determined by ELISA. b–d Correlation of serum HRF/TCTP levels with DAS28-CRP (n = 62) (b), DAS28-ESR (n = 62) (c), and serum IL-6 concentration in patients with RA (n = 60) (d). e Levels of HRF/TCTP in the joint fluids of healthy controls (HC, n = 5) and patients with osteoarthritis (OA, n = 9), early RA (ERA, n = 6), and advanced RA (ARA, n = 12). f HRF/TCTP expression in synovial tissue from patients with OA and RA, as determined by immunohistochemistry (left) and double immunofluorescence labeling (right) for CD55 (green) and HRF/TCTP (red). Scale bar: 100 μm. g, h Protein expression of the monomeric and dimeric forms of HRF/TCTP in OA-FLSs, RA-FLSs, and IL-1β-stimulated RA-FLSs, as determined by western blotting (g); relative density normalized to that of β-actin (h). Values are the mean ± SEM; *p < 0.05; ***p < 0.001 versus healthy controls (a, e) or OA-FLSs (h); ##p < 0.01; ###p < 0.001 versus the value before IL-1β stimulation (h).

Back to article page